Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia  

在线阅读下载全文

作  者:Ruth Stuckey Juan Francisco López-Rodríguez Santiago Sánchez-Sosa Adrián Segura-Díaz Nuria Sánchez-Farías Cristina Bilbao-Sieyro María Teresa Gómez-Casares 

机构地区:[1]Department of Hematology,Hospital Universitario de Gran Canaria Dr.Negrín,Las Palmas de Gran Canaria 35019,Spain

出  处:《World Journal of Clinical Oncology》2020年第12期996-1007,共12页世界临床肿瘤学杂志(英文版)

摘  要:Clinical trials have demonstrated that some patients with chronic myeloid leukemia(CML)treated for several years with tyrosine kinase inhibitors(TKIs)who have maintained a molecular response can successfully discontinue treatment without relapsing.Treatment free remission(TFR)can be reached by approximately 50%of patients who discontinue.Despite having similar levels of deep molecular response and an identical duration of treatment,the factors that influence the successful discontinuation of CML patients remain to be determined.In this review we will explore the factors identified to date that can help predict whether a patient will successfully achieve TFR.We will also discuss the need for the identification of predictive biomarkers associated with a high probability of achieving TFR for the future personalized identification of patients who are suitable for the discontinuation of TKI treatment.

关 键 词:Biomarkers Tyrosine kinase inhibitors Treatment discontinuation Molecular monitoring Duration of therapy LEUKEMIA MYELOGENOUS Chronic BCR-ABL positive 

分 类 号:R733.72[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象